AIMS/HYPOTHESIS: The fat-derived hormone leptin plays a crucial role in the maintenance of normal body weight and energy expenditure as well as in glucose homeostasis. Recently, it was reported that the liver-derived protein, insulin-like growth factor binding protein-2 (IGFBP-2), is responsible for at least some of the glucose-normalising effects of leptin. However, the exact mechanism by which leptin upregulates IGFBP-2 production is unknown. Since it is believed that circulating IGFBP-2 is predominantly derived from the liver and leptin has been shown to have both direct and indirect actions on the liver, we hypothesised that leptin signalling in hepatocytes or via brain-liver vagal efferents may mediate leptin control of IGFBP-2 production. METHODS: To address our hypothesis, we assessed leptin action on glucose homeostasis and plasma IGFBP-2 levels in both leptin-deficient ob/ob mice with a liver-specific loss of leptin signalling and ob/ob mice with a subdiaphragmatic vagotomy. We also examined whether restoring hepatic leptin signalling in leptin receptor-deficient db/db mice could increase plasma IGFBP-2 levels. RESULTS: Continuous leptin administration increased plasma IGFBP-2 levels in a dose-dependent manner, in association with reduced plasma glucose and insulin levels. Interestingly, leptin was still able to increase plasma IGFBP-2 levels and improve glucose homeostasis in both ob/ob mouse models to the same extent as their littermate controls. Further, restoration of hepatic leptin signalling in db/db mice did not increase either hepatic or plasma IGFBP-2 levels. CONCLUSIONS/ INTERPRETATION: Taken together, these data indicate that hepatic leptin signalling and subdiaphragmatic vagal inputs are not required for leptin upregulation of plasma IGFBP-2 nor blood glucose lowering in ob/ob mice.
AIMS/HYPOTHESIS: The fat-derived hormone leptin plays a crucial role in the maintenance of normal body weight and energy expenditure as well as in glucose homeostasis. Recently, it was reported that the liver-derived protein, insulin-like growth factor binding protein-2 (IGFBP-2), is responsible for at least some of the glucose-normalising effects of leptin. However, the exact mechanism by which leptin upregulates IGFBP-2 production is unknown. Since it is believed that circulating IGFBP-2 is predominantly derived from the liver and leptin has been shown to have both direct and indirect actions on the liver, we hypothesised that leptin signalling in hepatocytes or via brain-liver vagal efferents may mediate leptin control of IGFBP-2 production. METHODS: To address our hypothesis, we assessed leptin action on glucose homeostasis and plasma IGFBP-2 levels in both leptin-deficient ob/ob mice with a liver-specific loss of leptin signalling and ob/ob mice with a subdiaphragmatic vagotomy. We also examined whether restoring hepatic leptin signalling in leptin receptor-deficient db/db mice could increase plasma IGFBP-2 levels. RESULTS: Continuous leptin administration increased plasma IGFBP-2 levels in a dose-dependent manner, in association with reduced plasma glucose and insulin levels. Interestingly, leptin was still able to increase plasma IGFBP-2 levels and improve glucose homeostasis in both ob/ob mouse models to the same extent as their littermate controls. Further, restoration of hepatic leptin signalling in db/db mice did not increase either hepatic or plasma IGFBP-2 levels. CONCLUSIONS/ INTERPRETATION: Taken together, these data indicate that hepatic leptin signalling and subdiaphragmatic vagal inputs are not required for leptin upregulation of plasma IGFBP-2 nor blood glucose lowering in ob/ob mice.
Authors: Roberto Coppari; Masumi Ichinose; Charlotte E Lee; Abigail E Pullen; Christopher D Kenny; Robert A McGovern; Vinsee Tang; Shun M Liu; Thomas Ludwig; Streamson C Chua; Bradford B Lowell; Joel K Elmquist Journal: Cell Metab Date: 2005-01 Impact factor: 27.287
Authors: Ashok Sharma; Shoshana M Bartell; Clifton A Baile; Bo Chen; Robert H Podolsky; Richard A McIndoe; Jin-Xiong She Journal: PLoS One Date: 2010-08-16 Impact factor: 3.240
Authors: V E DeMambro; D R Clemmons; L G Horton; M L Bouxsein; T L Wood; W G Beamer; E Canalis; C J Rosen Journal: Endocrinology Date: 2008-02-14 Impact factor: 4.736
Authors: Víctor A Cortés; Kelly M Cautivo; Shunxing Rong; Abhimanyu Garg; Jay D Horton; Anil K Agarwal Journal: J Lipid Res Date: 2013-11-30 Impact factor: 5.922
Authors: Gang Xi; Melissa A Solum; Christine Wai; Laura A Maile; Clifford J Rosen; David R Clemmons Journal: Endocrinology Date: 2013-08-27 Impact factor: 4.736
Authors: Jeannette M Beasley; Nicole M Wedick; Swapnil N Rajpathak; Xiaonan Xue; Michelle D Holmes; Marc J Gunter; Judith Wylie-Rosett; Thomas E Rohan; Michael Pollak; Robert C Kaplan; Frank B Hu; Qi Sun; Howard D Strickler Journal: Growth Horm IGF Res Date: 2014-05-17 Impact factor: 2.372
Authors: Heather C Denroche; Whitney L Quong; Jennifer E Bruin; Eva Tudurí; Ali Asadi; Maria M Glavas; Jessica K Fox; Timothy J Kieffer Journal: Diabetes Date: 2013-05-08 Impact factor: 9.461
Authors: Heather C Denroche; Michelle M Kwon; Maria M Glavas; Eva Tudurí; Marion Philippe; Whitney L Quong; Timothy J Kieffer Journal: Mol Metab Date: 2016-06-24 Impact factor: 7.422